Skip to main content

Table 2 Baseline characteristics of patients with serous retinopathy compared with the overall coBRIM population

From: Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

 

Cobimetinib + vemurafenib recipients with SR (n = 63)

Placebo + vemurafenib recipients with SR (n = 7)

Overall coBRIM population (N = 493)

Age, years

 Median

59

62

55

 Range

30–78

33–76

23–88

Sex, n (%)

 Male

37 (58.7)

2 (28.6)

286 (57.8)

 Female

26 (41.3)

5 (71.4)

209 (42.2)

Region, n (%)

 Europe

51 (80.9)

5 (71.4)

366 (73.9)

 Australia/New Zealand

8 (12.7)

2 (28.6)

78 (15.8)

 North America

4 (6.4)

0

51 (10.3)

  1. SR serous retinopathy